These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28931292)

  • 21. The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer.
    Porres D; Pfister D; Thissen A; Kuru TH; Zugor V; Buettner R; Knuechel R; Verburg FA; Heidenreich A
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):85-92. PubMed ID: 27824042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is pelvic lymph node dissection required at radical prostatectomy for low-risk prostate cancer?
    Mitsuzuka K; Koie T; Narita S; Kaiho Y; Yoneyama T; Kawamura S; Tochigi T; Ohyama C; Habuchi T; Arai Y
    Int J Urol; 2013 Nov; 20(11):1092-6. PubMed ID: 23387553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.
    Narita T; Koie T; Ookubo T; Mitsuzuka K; Narita S; Yamamoto H; Inoue T; Hatakeyama S; Kawamura S; Tochigi T; Habuchi T; Arai Y; Ohyama C
    Med Oncol; 2017 Jan; 34(1):1. PubMed ID: 27889880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Removal of limited nodal disease in patients undergoing radical prostatectomy: long-term results confirm a chance for cure.
    Seiler R; Studer UE; Tschan K; Bader P; Burkhard FC
    J Urol; 2014 May; 191(5):1280-5. PubMed ID: 24262495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term Clinical Outcomes of Repeat Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: A Case Series.
    Grabbert M; Sigle A; Lang L; Büren MV; Mix M; Zamboglou C; Gratzke C; Schultze-Seemann W; Jilg CA
    Eur Urol Focus; 2022 Mar; 8(2):425-430. PubMed ID: 33858813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended pelvic lymph node dissection including internal iliac packet should be performed during robot-assisted laparoscopic radical prostatectomy for high-risk prostate cancer.
    Jung JH; Seo JW; Lim MS; Lee JW; Chung BH; Hong SJ; Song JM; Rha KH
    J Laparoendosc Adv Surg Tech A; 2012 Oct; 22(8):785-90. PubMed ID: 22967037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
    Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
    Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.
    Katz MS; Zelefsky MJ; Venkatraman ES; Fuks Z; Hummer A; Leibel SA
    J Clin Oncol; 2003 Feb; 21(3):483-9. PubMed ID: 12560439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE.
    Berglund RK; Sadetsky N; DuChane J; Carroll PR; Klein EA
    J Urol; 2007 Feb; 177(2):526-29; discussion 529-30. PubMed ID: 17222625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective lymph node dissection for castration-resistant prostate cancer.
    Busch J; Hinz S; Kempkensteffen C; Erber B; Klopf C; Weikert S; Miller K; Magheli A
    Urol Int; 2012; 88(4):441-6. PubMed ID: 22398510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.
    Mandel P; Rosenbaum C; Pompe RS; Steuber T; Salomon G; Chun FK; Graefen M; Huland H; Tilki D
    World J Urol; 2017 Dec; 35(12):1833-1839. PubMed ID: 28828530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review.
    Ploussard G; Gandaglia G; Borgmann H; de Visschere P; Heidegger I; Kretschmer A; Mathieu R; Surcel C; Tilki D; Tsaur I; Valerio M; van den Bergh R; Ost P; Briganti A;
    Eur Urol; 2019 Oct; 76(4):493-504. PubMed ID: 30391078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First case of 18F-FACBC PET/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer and negative 11C-choline PET/CT: new imaging techniques may expand pioneering approaches.
    Schiavina R; Concetti S; Brunocilla E; Nanni C; Borghesi M; Gentile G; Cevenini M; Bianchi L; Molinaroli E; Fanti S; Martorana G
    Urol Int; 2014; 92(2):242-5. PubMed ID: 24334968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease.
    Badani KK; Reddy BN; Moskowitz EJ; Paulucci DJ; Beksac AT; Martini A; Whalen MJ; Skarecky DW; Huynh LM; Ahlering TE
    Urol Oncol; 2018 Jun; 36(6):310.e1-310.e6. PubMed ID: 29625782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage Pelvic Lymph Node Dissection for Nodal Recurrence After Radical Prostatectomy Results in Minimal Clinical Benefit.
    Eastham JA
    Eur Urol; 2020 Nov; 78(5):670. PubMed ID: 32736930
    [No Abstract]   [Full Text] [Related]  

  • 36. Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes.
    Ledezma RA; Negron E; Razmaria AA; Dangle P; Eggener SE; Shalhav AL; Zagaja GP
    World J Urol; 2015 Nov; 33(11):1689-94. PubMed ID: 25701128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
    Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
    Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: A propensity score-matched analysis.
    Song C; Kang HC; Kim JS; Eom KY; Kim IA; Chung JB; Hong SK; Byun SS; Lee SE
    Strahlenther Onkol; 2015 Oct; 191(10):801-9. PubMed ID: 26159555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Number of metastatic lymph nodes as determinant of outcome after salvage radical prostatectomy for radiation-recurrent prostate cancer.
    Gugliemetti G; Sukhu R; Conca Baenas MA; Meeks J; Sjoberg DD; Eastham JA; Scardino PT; Touijer K
    Actas Urol Esp; 2016 Sep; 40(7):434-9. PubMed ID: 27184342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. De novo neurogenic bladder dysfunction after salvage lymph node dissection in patients with nodal recurrence of prostate cancer.
    Hanske J; Müller G; van Ophoven A; von Landenberg N; Roghmann F; Palisaar RJ; von Bodman C; Noldus J; Brock M
    Neurourol Urodyn; 2018 Aug; 37(6):1988-1995. PubMed ID: 29504654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.